Biosimilar infliximab use in paediatric IBD

BACKGROUND: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. ME...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Arch Dis Child
मुख्य लेखकों: Richmond, Lisa, Curtis, Lee, Garrick, Victoria, Rogers, Pam, Wilson, Michelle, Tayler, Rachel, Henderson, Paul, Hansen, Richard, Wilson, David C, Russell, Richard K
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMJ Publishing Group 2018
विषय:
Drug Therapy
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754881/
https://ncbi.nlm.nih.gov/pubmed/28988215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/archdischild-2017-313404
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन